Skip to main content
Figure 3 | BMC Immunology

Figure 3

From: Alteration of DSS-mediated immune cell redistribution in murine colitis by oral colostral immunoglobulin

Figure 3

Influence of prophylactically applied immunoglobulins and whole BC on clinical severity of DSS-induced colitis. The indicated therapeutics (sIgA, IgG, and BC) and control (NaCl) were applied parallel to DSS treatment. Negative control was represented from the therapeutic setting (NaClTh). Weight loss was either shown during the induction phase of colitis as percentage of body weight from day 1 (A) or as weight loss during the recovery phase as percentage body weight from day 8 (B). Clinical disease activity (DAI) (C) was determined by scoring changes in body weight, occult blood and stool consistency (D) as described in the Methods section. Values are mean ± SD of n = 8 (NaClTh), n = 6 (BC), n = 6-8 (sIgA), and n = 5-8 (IgG) mice.

Back to article page